Email this article CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
- Authors: Bulavina I.S.1, Krasilnikova S.Y.1
-
Affiliations:
- Sverdlovsk Regional Oncology Dispensary, Ekaterinburg
- Issue: Vol 1, No 1 (2012)
- Pages: 27-30
- Section: CASE REPORT
- Published: 26.02.2015
- URL: https://onco-surgery.info/jour/article/view/33
- DOI: https://doi.org/10.17650/2220-3478-2012-0-1-27-30
- ID: 33
Cite item
Full Text
Abstract
Bevacizumab in combination with standard chemotherapy (CT) in 1st line metastatic colorectal cancer (mCRC) settings prolongs median overall survival to 20,3 months. Data of observational cohort programs suggests that bevacizumab therapy beyond disease progression, in combination with several CT regimens prolongs median overall survival till 31,8 month. Authors presents their own experience of prolonged bevacizumab therapy in mCRC patient.
Keywords
About the authors
I. S. Bulavina
Sverdlovsk Regional Oncology Dispensary, Ekaterinburg
Email: fake@neicon.ru
Russian Federation
S. Y. Krasilnikova
Sverdlovsk Regional Oncology Dispensary, Ekaterinburg
Author for correspondence.
Email: skrasilnikova@mail.ru
Russian Federation
References
Supplementary files
